ATC Group: V09A Central nervous system

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of V09A in the ATC hierarchy

Level Code Title
1 V Various
2 V09 Diagnostic radiopharmaceuticals
3 V09A Central nervous system

Group V09A contents

Code Title
V09AA Technetium (99mTc) compounds
V09AB Iodine (123I) compounds
V09AX Other central nervous system diagnostic radiopharmaceuticals

Active ingredients in V09A

Active Ingredient

Florbetaben ¹⁸F binds to β-amyloid neuritic plaques in the brain. It is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment.

Florbetapir ¹⁸F binds to β-amyloid plaques and the ¹⁸F isotope produces a positron signal that is detected by a PET scanner. Florbetapir ¹⁸F is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.

Flutemetamol ¹⁸F binds to β-amyloid neuritic plaques in the brain. It is a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. VIZAMYL should be used in conjunction with a clinical evaluation.

Ioflupane ¹²³I is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected Parkinsonian syndromes (PS).

When technetium Tc 99m pertechnetate is added to exametazime in the presence of stannous reductant, a lipophilic technetium Tc 99m complex is formed. This lipophilic complex is the active moiety. The lipophilic technetium Tc 99m exametazime complex is taken up and retained in leukocytes. It is used for leukocyte (white blood cell) labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease.

Related product monographs

Document Type Information Source  
 AMYVID Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 CELSUNAX Solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 CERETEC Powder for solution for injection MPI, US: SPL/Old FDA, National Drug Code (US)
 DATSCAN Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 NEURACEQ Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 STRIASCAN Solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 TAUVID Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 ULTRA-TECHNEKOW FM Radionuclide generator MPI, EU: SmPC Health Products Regulatory Authority (IE)
 VIZAMYL Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)